LEXICON PHARMACEUTICALS, INC. Total Liabilities
LEXICON PHARMACEUTICALS, INC. (LXRX) had Total Liabilities of $75.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $75.53M.
- 2026-03-31: Liabilities $65.96M.
- 2025-12-31: Liabilities $77.45M.
- 2025-09-30: Liabilities $85.77M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $75.53M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $65.96M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $77.45M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $85.77M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $96.14M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $174.64M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $152.47M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $142.61M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $133.38M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $128.35M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $136.32M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $136.97M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $130.36M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $74.67M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $77.17M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $47.67M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $41.49M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $43.48M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $23.31M 10-K · filed 2023-03-03 | |
| 2021-09-30 | $35.73M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $34.44M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $40.71M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $47.42M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $91.29M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $333.23M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $315.79M 10-Q · filed 2020-04-27 | |
| 2019-12-31 | $300.61M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $279.88M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $298.03M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $304.20M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $310.54M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $339.59M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $338.01M 10-Q · filed 2018-07-30 | |
| 2018-03-31 | $360.62M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $368.27M 10-K · filed 2019-03-15 | $384.44M 10-K · filed 2018-03-01 |
| 2017-09-30 | $251.11M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $257.20M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $261.66M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $318.22M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $331.76M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $340.80M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $358.46M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $366.11M 10-K · filed 2017-03-06 | $368.98M 10-K · filed 2016-03-11 |
| 2015-09-30 | $193.20M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $184.49M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $187.07M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $187.36M 10-K · filed 2016-03-11 | |
| 2014-09-30 | $109.70M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $107.40M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $102.83M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $104.00M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $113.75M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $108.31M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $105.07M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $105.10M 10-K · filed 2014-03-07 | |
| 2012-09-30 | $105.08M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $136.16M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $133.82M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $132.94M 10-K · filed 2013-03-11 | |
| 2011-09-30 | $125.22M 10-Q · filed 2011-11-01 | |
| 2011-06-30 | $121.73M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $119.86M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |